Clinical Trials Logo

Clinical Trial Summary

Purpose: The primary purpose of this study is to measure pulmonary function, symptoms, and pulmonary inflammatory responses in healthy young adults during and immediately after exposure to a low concentration of ozone (0.070 ppm) or clean air for 6.6 hours while undergoing moderate intermittent exercise. This concentration is the current EPA NAAQS standard for ozone.


Clinical Trial Description

Potential health effects of ozone have been extensively studied over decades at various levels of exposure concentration and for varying time periods in young healthy adult subjects. Effects of ozone have been well documented particularly for decrements of lung function and an influx of neutrophils and other markers of pulmonary inflammation. The majority of those studies were done at ozone concentrations between 0.12 and 0.40 ppm, considerably higher than the current EPA NAAQS ozone standard of 0.070 ppm, and at exposure durations of two hours, even though the current standard is an 8-hour standard. However, a small number of studies have assessed changes in lung function following exposure to low levels of ozone for several hours. These latter studies have shown that exposure to ozone for 6.6 hours at concentrations between 0.06 and 0.08 ppm causes mild reversible decrements in lung function (1.7-10%) as measured by forced vital capacity (FVC) and forced expired volume at 1 s (FEV1) immediately after exposure in healthy young adults. In addition, in one study an increase in ozone-induced neutrophils was seen in induced sputum following exposure to 0.06 ppm ozone (8) and in bronchoalveolar lavage fluid) following exposure to 0.08 ppm ozone (9). The EPA is considering whether the current ozone NAAQS standard at 0.070 is protective and has asked EPA researchers to conduct a study similar to those done at 0.06 and 0.08 ppm. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05680831
Study type Interventional
Source Environmental Protection Agency (EPA)
Contact Martin W Case, B.S.
Phone 919-966-6211
Email case.martin@epa.gov
Status Recruiting
Phase Phase 1
Start date October 13, 2022
Completion date February 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT04892004 - Symptom Recognition Improves Self-care in Patients With Heart Failure. N/A
Recruiting NCT06446999 - Yoga-Based Breathing Exercise, Colorectal Cancer Surgery N/A
Not yet recruiting NCT05505188 - Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer N/A
Completed NCT04864600 - CANDLE - A Study of Acute Health Effects of Exposure to Particles Generated by Candles N/A
Completed NCT03336177 - Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients.
Completed NCT06395025 - Blinded User Study for the Evaluation of the Acceptability and Efficacy of One Medical Device in Venous Return in Comparison With a Control Group N/A
Completed NCT04292665 - Effects of Classical Massage and Benson Relaxation Exercise on Heart Failure Patients N/A
Recruiting NCT05681975 - Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
Completed NCT04169919 - Modified Treatment for Epidemic Keratoconjunctivitis (EKC) N/A
Recruiting NCT06436651 - Digital Storytelling in Symptom Management Pediatric Oncology N/A
Recruiting NCT04940780 - Integrative Oncology for Patient Symptoms N/A
Not yet recruiting NCT05837988 - Construction of Symptom Network in Maintenance Hemodialysis Patients
Recruiting NCT05092568 - Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Recruiting NCT03968718 - PATIENT VOICES Integration of Systematic Assessment of Patient Reported Outcomes Within Clinical Oncology Practice N/A
Completed NCT05556707 - Symptom Clusters and Risk Factors of COVID-19 Patients
Completed NCT06153680 - Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return N/A
Completed NCT04873349 - Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients N/A
Recruiting NCT06136221 - Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease N/A
Recruiting NCT05827406 - A Useful Support System for Psychiatric Diagnostics and Follow-up in Adult Psychiatry and Primary Care (ASPP)
Completed NCT06215339 - Diet Therapy in Hemodialysis Patients N/A